Ever Supreme Bio Technology Co., Ltd. (6712) AI Stock Analysis

Ever Supreme Bio Technology Co., Ltd.

(TPEx:6712)

Select Model

Rating:73Outperform

Price Target:TWD 161.00▲(8.78% Upside)

Action:initiatedcoverage

Date:11/09/26

The score is driven primarily by excellent fundamentals: high and sustained margins, a near debt-free balance sheet, strong cash conversion and a 28% return on equity. Valuation is reasonable at 28.8x earnings with a 2.2% dividend yield supported by robust free cash flow. The main drag is technical weakness — the share price has fallen below its key short- and medium-term moving averages with negative MACD momentum, although oversold RSI and Stochastic readings suggest selling pressure may be nearing exhaustion. Secondary concerns include slowing revenue growth, modest operating margin compression and a shrinking equity base. No earnings call or corporate event data was available, so those components were excluded and their weight redistributed.

Positive Factors

Revenue GrowthMaterial multi-year revenue scaling indicates the company has expanded its business base and maintained demand into 2025. Continued top-line growth can support operating leverage, reinvestment, and stronger competitive positioning over the next several quarters.

Negative Factors

Declining Free Cash FlowThe year-over-year free-cash-flow decline indicates that cash conversion has weakened from the prior period, potentially reflecting normalization, investment, or working-capital pressure. Persistent deterioration would reduce internally funded growth and weaken capital-allocation flexibility.

Ever Supreme Bio Technology Co., Ltd. (6712) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 14.72B
Dividend Yield: 2.14%
Average Volume (3M): 251.12K
Price to Earnings (P/E): 30.9
Beta (1Y): 0.41
Revenue Growth: 13.26%
EPS Growth: -15.91%
Country: TW
Employees: 88
Sector: General
Sector Strength: 55
Industry: Biotechnology

Ever Supreme Bio Technology Co., Ltd. Business Overview & Revenue Model

Company Description

This enterprise is dedicated to the investigation, advancement, and creation of pharmaceutical treatments leveraging human mesenchymal stem cells and immune cells. Its current portfolio features UMC01, a drug candidate undergoing Phase I clinical eva...

Ever Supreme Bio Technology Co., Ltd. Financial Statement Overview

Summary

Ever Supreme combines rapid multi-year revenue growth (NT$71M in 2020 to NT$1.02B) with exceptional profitability — roughly 71% gross, 43% operating and 42% net margins — and a virtually debt-free balance sheet (debt-to-equity near 0.03). Return on equity of about 28% and free cash flow of NT$531M covering nearly all reported net income confirm high earnings quality. Offsetting these strengths are decelerating revenue growth (9% versus 23% the prior year), operating margin compression from 49% to 43%, lumpy bottom-line results driven by non-core items, and a shareholders' equity base that has contracted for three consecutive years.

Income Statement

82Very Positive

Balance Sheet

85Very Positive

Cash Flow

87Very Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.08B	1.02B	933.81M	758.39M	627.51M	438.84M
Gross Profit	793.91M	721.33M	660.04M	484.75M	414.56M	245.48M
EBITDA	550.90M	462.17M	491.76M	655.52M	300.16M	433.26M
Net Income	473.27M	429.43M	367.25M	539.40M	200.71M	369.60M
Balance Sheet
Total Assets	3.54B	2.00B	2.14B	2.08B	1.97B	2.02B
Cash, Cash Equivalents and Short-Term Investments	1.06B	435.66M	938.17M	1.34B	1.27B	1.34B
Total Debt	232.54M	38.75M	2.84M	5.90M	17.86M	34.42M
Total Liabilities	723.80M	477.80M	341.82M	232.96M	181.45M	124.83M
Stockholders Equity	2.81B	1.53B	1.79B	1.84B	1.79B	1.90B
Cash Flow
Free Cash Flow	630.61M	530.62M	434.78M	415.91M	313.61M	131.04M
Operating Cash Flow	631.54M	536.35M	440.34M	421.74M	319.20M	135.69M
Investing Cash Flow	68.80M	134.27M	-23.46M	61.60M	-287.31M	-296.83M
Financing Cash Flow	-289.49M	-750.13M	-451.64M	-500.47M	-319.43M	733.36M

Ever Supreme Bio Technology Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6712 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:6712	73Outperform	TWD 14.92B	30.86	―	2.14%	13.26%	-15.91%
TW:1789	57Neutral	TWD 16.01B	904.98	―	1.45%	-4.75%	-90.91%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

TW:6712 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6712	Ever Supreme Bio Technology Co., Ltd.	148.00	-3.92	-2.58%
TW:1789	Scinopharm Taiwan, Ltd.	20.00	2.60	14.92%
TW:6586	CHO Pharma, Inc.	76.20	46.05	152.74%
TW:6589	EirGenix, Inc.	51.70	-22.80	-30.60%
TW:7729	Steminent Biotherapeutics, Inc.	247.00	203.91	473.19%
TW:7827	HanchorBio Inc.	119.00	49.90	72.21%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Ever Supreme Bio Technology Co., Ltd. AI Stock Analysis